EUR 0.44
(0.0%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 14.33 Million EUR | 40.75% |
2022 | 10.18 Million EUR | 13.16% |
2021 | 9 Million EUR | -16.23% |
2020 | 10.74 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 8.67 Million EUR | 0.0% |
2024 Q1 | 8.67 Million EUR | -39.51% |
2023 FY | 14.33 Million EUR | 40.75% |
2023 Q3 | 14.33 Million EUR | -9.59% |
2023 Q1 | 15.85 Million EUR | 55.67% |
2023 Q4 | 14.33 Million EUR | 0.0% |
2023 Q2 | 15.85 Million EUR | 0.0% |
2022 Q4 | 10.18 Million EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Nicox S.A. | 25.15 Million EUR | 42.997% |
European Medical Solutions | 12.71 Million EUR | -12.756% |
argenx SE | 15.35 Million EUR | 6.617% |
BioSenic S.A. | 15.57 Million EUR | 7.93% |
Celyad Oncology SA | 902 Thousand EUR | -1489.579% |
Hyloris Pharmaceuticals SA | 344 Thousand EUR | -4068.023% |
Onward Medical N.V. | 16.3 Million EUR | 12.069% |
Oxurion NV | 117 Thousand EUR | -12154.701% |
PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -103.954% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 2.87 Billion EUR | 99.502% |